美股异动 | 礼来(LLY.US)大跌近14% 口服减肥药疗效不及预期

Core Viewpoint - Eli Lilly's stock dropped nearly 14% to $642.12 following disappointing results from a late-stage study of its experimental oral weight-loss drug orforglipron, which showed a weight reduction of approximately 11%, falling short of Wall Street expectations [1] Group 1: Drug Performance - The highest dosage of orforglipron helped patients achieve an average weight loss of 12.4% over 72 weeks [1] - Analysts had anticipated orforglipron to perform similarly to Novo Nordisk's Wegovy, which achieved a 14.9% weight loss over 68 weeks in a 2021 trial [1] - Some analysts even expected orforglipron to exceed the performance of Novo Nordisk's popular product [1]